Dr. Srivastava is currently the Chief Scientific Officer at Perpetual Medicines in Raleigh, USA. He has more than 25 years of experience in the discovery and development of peptide therapeutics. He joined Perpetual from Aktis Oncology. He has served as Head of Peptide Chemistry at both GlaxoSmithKline (USA) and Amylin Pharmaceuticals.  He was also a co-founder at Phoundry Pharmaceuticals and Vice President of Chemistry at both Intarcia and Aktis. Ved is a former president of the American Peptide Society (APS).  He was instrumental in the development of several peptide-based drugs, including Byetta™, Symlin™ and Bydureon™. Ved has co-authored and published numerous peer-reviewed manuscripts and patents. He is the Editor of six influential books on peptide-based drug discovery and development.